author-photo

Adam Giermasz

University of California, Davis

18

Papers

439

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.

2021 Haemophilia
Show All
- Source
- Cite
- Save
Citations (0)
Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors with or without Prophylactic Treatment

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Activity of Transgene-Produced B-Domain Deleted Factor VIII in Human Plasma Following AAV5 Gene Therapy.

2020 Blood
Show All
- Source
- Cite
- Save
Citations (13)
Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year

2019 Blood
Show All
- Source
- Cite
- Save
Citations (11)
Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A

2019 Blood
Show All
- Source
- Cite
- Save
Citations (8)
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B

2019 Blood Advances
Show All
- Source
- Cite
- Save
Citations (30)
Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies

2018 Blood
Show All
- Source
- Cite
- Save
Citations (4)